Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia

Heart

Volumn 86, Issue 5, 2001, Pages 522-526

  Cobbe, S M ^a   Campbell, R W F ^b   Camm, A J ^c   Nathan, A W ^d   Rowland, E ^e   Bloch Thomsen, P E ^f   Moller M ^g   Jordaens, L ^h  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Atrioventricular re entrant tachycardia; Dofetilide; Refractory period

Indexed keywords

DOFETILIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART BUNDLE BRANCH BLOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REENTRY TACHYCARDIA; REFRACTORY PERIOD; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0034783999     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.86.5.522     Document Type: Article

References (27)

1. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial
2. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia
3. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
4. Efficacy of sotalol in controlling reentrant supraventricular tachycardias
5. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
6. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
7. Adverse effects of low dose amiodarone: A meta-analysis
8. Antiarrhythmic treatment of atrioventricular tachycardias
9. + current in cardiac myocytes by dofetilide
10. UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells
11. Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris
12. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias
13. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
14. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter
15. Conversion of AF and maintenance of sinus rhythm by dofetilide
16. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: A multicenter study
17. Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay
18. The Sicilian Gambit A. new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
19. Using the right drug: A treatment algorithm for regular supraventricular tachycardias
20. Role of alterations in refractoriness and conduction in the genesis of reentrant arrhythmias. Implications for antiarrhythmic effects of class III drugs
21. Chemical cardioversion of atrial fibrillation with intravenous dofetilide
22. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter
23. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug
24. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome
25. Efficacy of ajmaline and propafenone in patients with accessory pathways: A prospective randomized study
26. Supraventricular tachycardia and pre-excitation syndromes: Pharmacological therapy
27. Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome